Limosilactobacillus reuteri DSM 17938-Containing Infant Formulas and the Associations with Gastrointestinal Tolerance: A Cross-Sectional Observational Study
- PMID: 36771237
- PMCID: PMC9919438
- DOI: 10.3390/nu15030530
Limosilactobacillus reuteri DSM 17938-Containing Infant Formulas and the Associations with Gastrointestinal Tolerance: A Cross-Sectional Observational Study
Abstract
Limosilactobacillus (L.; previously Lactobacillus) reuteri has been shown to influence gastrointestinal (GI) tolerance. This study was a secondary analysis of GI tolerance data from a multi-country, cross-sectional, observational study in healthy infants using the validated Infant Gastrointestinal Symptom Questionnaire (IGSQ) and a gut comfort questionnaire. Breastfed infants (BFI; n = 760) were compared to formula-fed infants receiving either L. reuteri-containing formula (FFI + LR; n = 470) or standard formula without any probiotic or prebiotic (FFI-Std; n = 501). The IGSQ composite scores (adjusted mean ± SE) in FFI + LR (22.17 ± 0.39) was significantly lower than in FFI-Std (23.41 ± 0.37) and similar to BFI (22.34 ± 0.30;), indicating better GI tolerance in FFI + LR than in FFI-Std. Compared with FFI-Std, FFI + LR had lower reports of difficulty in passing stools (11% vs. 22%; adjusted-odds ratio (OR) (95%CI) = 0.46 (0.31-0.68)), fewer hard stools (mean difference = -0.12 (-0.21, -0.02)) and less physician-confirmed colic (OR = 0.61 (0.45-0.82)), and similar to BFI. Parent-reported crying time (mean difference = -0.15 (-0.28, -0.01)), frequency of spitting-up/vomiting (mean difference = -0.18 (-0.34, -0.03)), volume of spit-up (mean difference = -0.20 (-0.32, -0.08)) and fussiness due to spitting-up/vomiting (mean difference = -0.17 (-0.29, -0.05)) were lower in FFI + LR versus FFI-Std and similar to BFI. In this study, L. reuteri-containing formula was associated with improved digestive tolerance and behavioral patterns.
Keywords: colic; gastrointestinal tolerance; infant; infant formula; nutrition; probiotics.
Conflict of interest statement
L. Lavalle, N. Sauvageot, CI. Cercamondi, D. Egli, I. Jankovic are or were current employees of Société des Produits Nestlé S.A., Vevey, Switzerland. Y. Vandenplas has participated as a clinical investigator and/or advisory board member and/or consultant and/or speaker for Abbott Nutrition, Ausnutria, Biogaia, By Heart, CHR Hansen, Danone, ELSE Nutrition, Friesland Campina, Nestle Health Science, Nestle Nutrition Institute, Nutricia, Mead Johnson Nutrition, Pileje, United Pharmaceuticals (Novalac), Yakult and Wyeth.
Figures



Similar articles
-
Infant feeding practice and gastrointestinal tolerance: a real-world, multi-country, cross-sectional observational study.BMC Pediatr. 2022 Dec 14;22(1):714. doi: 10.1186/s12887-022-03763-8. BMC Pediatr. 2022. PMID: 36514058 Free PMC article.
-
Efficacy of a partially hydrolysed formula, with reduced lactose content and with Lactobacillus reuteri DSM 17938 in infant colic: A double blind, randomised clinical trial.Clin Nutr. 2021 Feb;40(2):412-419. doi: 10.1016/j.clnu.2020.05.048. Epub 2020 Jun 12. Clin Nutr. 2021. PMID: 32600858 Clinical Trial.
-
Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial.BMJ. 2014 Apr 1;348:g2107. doi: 10.1136/bmj.g2107. BMJ. 2014. PMID: 24690625 Free PMC article. Clinical Trial.
-
Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis.Pediatrics. 2018 Jan;141(1):e20171811. doi: 10.1542/peds.2017-1811. Pediatrics. 2018. PMID: 29279326 Review.
-
Probiotics to prevent infantile colic.Cochrane Database Syst Rev. 2019 Mar 13;3(3):CD012473. doi: 10.1002/14651858.CD012473.pub2. Cochrane Database Syst Rev. 2019. PMID: 30865287 Free PMC article.
Cited by
-
Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial.Eur J Pediatr. 2024 Dec;183(12):5371-5381. doi: 10.1007/s00431-024-05806-x. Epub 2024 Oct 11. Eur J Pediatr. 2024. PMID: 39390276 Free PMC article. Clinical Trial.
-
Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms.Front Cell Infect Microbiol. 2023 Aug 18;13:1254198. doi: 10.3389/fcimb.2023.1254198. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37662007 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials